1-Amino-2-phenyl-pyrrolidin | 3237-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-Amino-2-phenyl-pyrrolidin
• 英文别名: 2-phenyl-pyrrolidin-1-ylamine；2-Phenyl-1-pyrrolidinamine；2-phenylpyrrolidin-1-amine
• CAS: 3237-86-3
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: PRKFHQWMICWPRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：GAVARDINAS Konstantinos

  公开号：US20090163472A1

  公开（公告）日：2009-06-25

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式(I)化合物： 或其药学上可接受的盐；包含式(I)化合物与适宜载体、稀释剂或赋形剂的药物组合物；以及治疗生理障碍，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括给予式(I)化合物或其药学上可接受的盐。
• LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONATING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS
  申请人：Mitsui Chemicals, Inc.

  公开号：EP2199313A1

  公开（公告）日：2010-06-23

  The invention aims to provide latent curing agents which exert high low-temperature curing properties when used together with ionically polymerizable compounds and which exhibit high storage stability at room temperature. Latent curing agents for ionically polymerizable compounds which agents each contain a hydroxyl-free amine imide compound having an N-N bond energy of 100 to 210 kJ/mol as determined by B3LYP functional theory method.

  本发明旨在提供与离子可聚合化合物一起使用时具有较高低温固化性能，并且在室温下具有较高储存稳定性的潜在固化剂。用于离子可聚合化合物的潜在固化剂，每种固化剂都含有一种无羟基胺亚胺化合物，根据 B3LYP 功能理论方法测定，其 N-N 键能量为 100 至 210 kJ/mol。
• 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists
  申请人：Eli Lilly and Company

  公开号：EP2537845A1

  公开（公告）日：2012-12-26

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐；药物组合物，包括与合适的载体、稀释剂或赋形剂结合的式 (I) 化合物；以及治疗生理紊乱，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括施用式 (I) 化合物或其药学上可接受的盐。
• 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP2235007B1

  公开（公告）日：2012-10-31
• 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：Eli Lilly and Company

  公开号：EP2537845B1

  公开（公告）日：2014-03-19